WO2015179823A3 - Lung localized inhibitors of alpha(v)beta 6 - Google Patents

Lung localized inhibitors of alpha(v)beta 6 Download PDF

Info

Publication number
WO2015179823A3
WO2015179823A3 PCT/US2015/032275 US2015032275W WO2015179823A3 WO 2015179823 A3 WO2015179823 A3 WO 2015179823A3 US 2015032275 W US2015032275 W US 2015032275W WO 2015179823 A3 WO2015179823 A3 WO 2015179823A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung
beta
alpha
localized
inhibitors
Prior art date
Application number
PCT/US2015/032275
Other languages
French (fr)
Other versions
WO2015179823A2 (en
WO2015179823A8 (en
Inventor
Arnab K. Chatterjee
Lukes LAIRSON
Natasha LUCKI
Joshua David SEITZ
Peter G. Schultz
Original Assignee
The California Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The California Institute For Biomedical Research filed Critical The California Institute For Biomedical Research
Publication of WO2015179823A2 publication Critical patent/WO2015179823A2/en
Publication of WO2015179823A3 publication Critical patent/WO2015179823A3/en
Publication of WO2015179823A8 publication Critical patent/WO2015179823A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are compounds, compositions, and methods of their use treatment of a lung disease.
PCT/US2015/032275 2014-05-23 2015-05-22 Lung localized inhibitors of alpha(v)beta 6 WO2015179823A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002621P 2014-05-23 2014-05-23
US62/002,621 2014-05-23

Publications (3)

Publication Number Publication Date
WO2015179823A2 WO2015179823A2 (en) 2015-11-26
WO2015179823A3 true WO2015179823A3 (en) 2016-05-19
WO2015179823A8 WO2015179823A8 (en) 2016-08-11

Family

ID=54554981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032275 WO2015179823A2 (en) 2014-05-23 2015-05-22 Lung localized inhibitors of alpha(v)beta 6

Country Status (1)

Country Link
WO (1) WO2015179823A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47692A (en) 2017-02-28 2020-01-08 Morphic Therapeutic Inc INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
KR102605460B1 (en) 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 Integrin Inhibitor
CR20200178A (en) 2017-11-01 2020-06-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
CN118184532A (en) 2018-12-12 2024-06-14 中外制药株式会社 Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same
WO2024105197A1 (en) 2022-11-17 2024-05-23 Vincerx Pharma Gmbh Small molecule-drug-conjugates cleavable in a tumor microenvironment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036003A2 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US20040092454A1 (en) * 2001-03-16 2004-05-13 Oliver Schadt Inhibitors of integrin alphavbeta6
WO2007107706A2 (en) * 2006-03-17 2007-09-27 Argenta Discovery Limited Dimers of heterocyclic compounds for the treatment of copd
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
US20120244074A1 (en) * 2009-12-17 2012-09-27 Magne Solbakken Labelled integrin binders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036003A2 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US20040092454A1 (en) * 2001-03-16 2004-05-13 Oliver Schadt Inhibitors of integrin alphavbeta6
WO2007107706A2 (en) * 2006-03-17 2007-09-27 Argenta Discovery Limited Dimers of heterocyclic compounds for the treatment of copd
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
US20120244074A1 (en) * 2009-12-17 2012-09-27 Magne Solbakken Labelled integrin binders

Also Published As

Publication number Publication date
WO2015179823A2 (en) 2015-11-26
WO2015179823A8 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3448874A4 (en) Compositions for the treatment of disease
EP3448875A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EP4006016A3 (en) Probes for imaging huntingtin protein
MX2017008456A (en) Fused bicyclic compounds for the treatment of disease.
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
EP3139935A4 (en) Therapeutic placental compositions, methods of making and methods of use
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
IL252897A0 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
MX2017012342A (en) Fused bicyclic compounds for the treatment of disease.
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
EP3638252A4 (en) Sting-dependent activators for treatment of disease
EP3820477A4 (en) Compounds, compositions, and methods for the treatment of disease
EA201700254A1 (en) COMBINATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15795566

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15795566

Country of ref document: EP

Kind code of ref document: A2